Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03228134
Other study ID # 2017LCSY347
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date February 1, 2018
Est. completion date September 2024

Study information

Verified date May 2023
Source Shanghai University of Traditional Chinese Medicine
Contact Zifeng Ma, Doctor
Phone +8621-64385700
Email mzf05@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Investigators aimed to evaluate the clinical efficacy of integrated traditional Chinese and Western medicine in the treatment of asthma, and to further optimize the prescription of Chinese medicine treatment.


Description:

The incidence of asthma in China is high and the rate of control is low. Traditional Chinese medicine has a long history of treating asthma, and has a good clinical curative effect.The purpose of this study is to evaluate the clinical efficacy of traditional Chinese medicine in the treatment of asthma, and to further optimize the prescription of Chinese medicine treatment. In this study, investigators recruited chronic persistent asthma participants, and gave the corresponding western medicine background treatment and traditional Chinese medicine treatment program for 28 days.Participants will undergo a physical examination, lung function, blood and sputum collection.


Recruitment information / eligibility

Status Recruiting
Enrollment 320
Est. completion date September 2024
Est. primary completion date September 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Patient diagnosed with chronic persistent asthma - Patients had positive bronchodilator reversibility test or positive bronchial challenge test or more than 50 parts per billion of FENO before - Conform to the predetermined 2 TCM Syndrome Types - Patients who have given written informed consent Exclusion Criteria: - Smoking and continuous exposure to hazardous environment - With fever, or severity of intermittent state, high degree of sustained, or with respiratory failure, etc. - Pulmonary emphysema, chronic obstructive pulmonary disease, pulmonary emphysema, pulmonary heart disease, pneumonia, lung cancer and other lung diseases - Patients who are allergic to therapeutic medicine

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ke Chuan Liu Wei Granule
Traditional Chinese Medicine
Yang He Ping Chuan Granule
Traditional Chinese Medicine
Other:
Ke Chuan Liu Wei Granule placebo
Placebo
Yang He Ping Chuan Granule placebo
Placebo

Locations

Country Name City State
China Fenglin Street Community Health Service Center Shanghai Shanghai
China Fengxian District Hospital of TCM Shanghai Shanghai
China Kangjian Street Community Health Service Center Shanghai Shanghai
China Longhua Hospital Affiliated Shanghai University of TCM Shanghai Shanghai
China Tianping Street Community Health Service Center Shanghai Shanghai

Sponsors (2)

Lead Sponsor Collaborator
Shanghai University of Traditional Chinese Medicine Longhua Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Asthma control rate change Measured the change from Baseline of asthma control rate up to 4 weeks
Secondary Lung function(FEV1, PEF) Measured routine pulmonary ventilation function test Up to 4 weeks
Secondary FeNO The fractional concentration of exhaled nitric oxide Up to 4 weeks
Secondary Blood routine examination Hematological routine examination Up to 4 weeks
Secondary Liver function test Simple liver function test Up to 4 weeks
Secondary Cytokine levels of induced sputum Measured cytokine levels of induced sputum supernatant Up to 4 weeks
Secondary Kidney function test Simple kidney function test Up to 4 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT02934945 - Treatment Efficacy of Budesonide/Formoterol in Cough Variant Asthma and Typical Asthma Patients Phase 4
Completed NCT02561351 - Correlation Between Fractional Exhaled Nitric Oxide (FeNO) Levels and Asthma Exacerbation N/A
Recruiting NCT01759472 - Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Provocation Test N/A
Completed NCT01918293 - Self-Management Using Smartphone Application for Chronic Disease Care in Real siTuation (SMART-Asthma): Adult N/A
Completed NCT01203904 - Pulmicort Turbuhaler 100/200 Specific Clinical Experience Investigation N/A
Completed NCT01762917 - Influence of Bag Volume Variation on the Reproducibility of Inert Gas Rebreathing N/A
Completed NCT00536731 - Symbicort Rapihaler Therapeutic Equivalence Study Phase 3
Completed NCT00930826 - Childhood Asthma and Schooling: The Truth Unveiled N/A
Completed NCT00331929 - Respiratory Health Study of Children in Kiryat Tivon N/A
Completed NCT00327028 - Study of Efficacy of Phenytoin in Therapy of Patients With Bronchial Asthma Phase 4
Completed NCT00413387 - Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®) Phase 3
Completed NCT00950794 - Study of Salmeterol (SN408D) for Adult Asthma Phase 4
Completed NCT00153283 - Study of Efficacy of Gabapentin in Therapy of Bronchial Asthma Phase 4
Completed NCT00142025 - Study of Efficacy of Oxcarbazepine in Therapy of Bronchial Asthma Phase 4
Completed NCT00153270 - Study of Efficacy of Sodium Valproate in Therapy of Bronchial Asthma Phase 4
Completed NCT03450434 - XC8 in the Treatment of Patients With Bronchial Asthma Phase 2
Recruiting NCT05189613 - Mepolizumab Effectiveness in Severe Eosinophilic Asthma and Bronchiectasis N/A
Recruiting NCT04128111 - Study on the Correlation Between TCM Syndrome, Inflammatory Phenotype and Biomarker of Bronchial Asthma
Completed NCT06326632 - Comparative Effectiveness Study of Constant-Load Versus Graded Aerobic Exercise in Obese Children With Bronchial Asthma N/A
Completed NCT05088512 - The Role of Genetic Factors in the Development of Bronchial Asthma in the Kazakh Population